Fig 1: Changes in LDL-cholesterol and MIG6 concentrations during treatment with rosuvastatin or rosuvastatin/ezetimibe. (a) LDL-cholesterol concentration before and after 12 weeks of treatment in the two groups. (b) MIG6 concentrations before and after 12 weeks of treatment in the two groups. R group, rosuvastatin monotherapy group; RE group, rosuvastatin/ezetimibe combination group; LDL, low-density lipoprotein; MIG6, protein encoded by mitogen-inducible gene 6. Data are mean ± SEM and were analyzed using Student’s t-test or the Mann–Whitney U test. * Before vs. After, P < 0.05; **R group vs. RE group, P < 0.05.
Fig 2: Changes in LDL-cholesterol and MIG6 concentrations during the statin-based treatment of hypercholesterolemia. (a) LDL-cholesterol concentration before and after 12 weeks of treatment. (b) MIG6 concentration before and after 12 weeks of treatment. Data are mean ± SEM and were analyzed using Student’s t-test. *Before vs. After, P < 0.05. LDL, low-density lipoprotein; MIG6, protein encoded by mitogen-inducible gene 6.
Fig 3: Effects of cholesterol-lowering treatment in participants categorized according to their pre-treatment MIG6 concentrations. (a) Entire cohort, (b) R group, (c) RE group. R group, rosuvastatin monotherapy group; RE group, rosuvastatin/ezetimibe combination group; basal MIG6 Hi, high basal MIG6 group; basal MIG6 Lo, low basal MIG6 group. LDL, low-density lipoprotein; MIG6, protein encoded by mitogen-inducible gene 6. Data are mean ± SEM and were analyzed using Student’s t-test or the Mann–Whitney U test. *Before vs. After, P < 0.05; **basal MIG6 Hi vs. basal MIG6 Lo, P < 0.05.
Fig 4: MIG6 concentration before and after treatment in participants categorized according to the size of the reduction in LDL-cholesterol. (a) Entire cohort, (b) R group, and (c) RE group. R group, rosuvastatin monotherapy group; RE group, rosuvastatin/ezetimibe combination group; LDL-C ↓ ≥50%, LDL-C reduction ≥50% group; LDL-C ↓ <50%, LDL-C reduction <50% group. LDL, low-density lipoprotein cholesterol; MIG6, protein encoded by mitogen-inducible gene 6. Data are mean ± SEM and were analyzed using Student’s t-test or the Mann–Whitney U test. * Before vs. After, P < 0.05.
Fig 5: Graphs (A–C) present the receiver operating characteristic curves for the prediction of 6-month mortality. (A) The single factors, such as ERBB2, NRG4, and MIG6, were compared to each other, and (B) multiplied values were also compared. Although the comparison between single factors and the comparison between multiplied values did not show a significant difference, (C) the product of ERBB2 and NRG4 with MIG6 (AUC 0.940)/without MIG6 (AUC 0.942) showed superior results in AUC compared to the results for alpha-fetoprotein (AUC 0.727). (ERBB2, erythroblastic leukemia viral oncogene homolog 2; NRG4, neuregulin 4; MIG6, mitogen-inducible gene 6; AUC, area under the curve; red dotted line in the figure, random classifier).
Supplier Page from Wuhan Fine Biotech Co., Ltd. for Human ERRFI1(ERBB receptor feedback inhibitor 1) ELISA Kit